Antioxidants, NFκB activation, and diabetogenesis

Proceedings of the Society for Experimental Biology and Medicine

Volumn 222, Issue 3, 1999, Pages 205-213

  Ho, Emily ^a   Bray, Tammy M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR;

AUTOIMMUNE DISEASE; CONFERENCE PAPER; DIABETOGENESIS; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; RISK FACTOR; ANIMAL; METABOLISM; PANCREAS ISLET; PHYSIOLOGY; REVIEW;

ANIMALIA;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 1; HUMANS; INFLAMMATION; ISLETS OF LANGERHANS; NF-KAPPA B; REACTIVE OXYGEN SPECIES;

EID: 0032589599     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.1999.d01-137.x     Document Type: Conference Paper

References (103)

1. Oberley LW. Free radicals and diabetes. Free Radic Biol Med 5:113-124, 1988.
2. Rabinovitch A. Free radicals as mediators of pancreatic islet β-cell injury in autoimmune diabetes [editorial; comment]. J Lab Clin Med 119:455-456, 1992.
3. Ludvigsson J. Intervention at diagnosis of type I diabetes using either antioxidants or photopheresis. Diabetes Metab Rev 9:329-336, 1993.
4. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: Which role for oxidative stress? Metabolism 44:363-368, 1995.
5. Virtanen SM, Aro A. Dietary factors in the aetiology of diabetes. Ann Med 26:469-178, 1994.
6. Corbett JA, McDaniel ML. Does nitric oxide mediate autoimmune destruction of β cells? Possible therapeutic interventions in IDDM. Diabetes 41:897-903, 1992.
7. Doly M, Droy-Lefaix MT, Braquet P. Oxidative stress in diabetic retina. EXS 62:299-307, 1992.
8. Chisolm GM, Irwin KC, Penn MS. Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 41(Suppl 2):S61-S66, 1992.
9. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 10:339-352, 1991.
10. Nerup J, Mandrup-Poulsen T, Molvig J, Helqvist S, Wogensen L, Egeberg J. Mechanisms of pancreatic β-cell destruction in type I diabetes. Diabetes Care 11(Suppl 1):S16-S23, 1988.
11. Gillery P, Monboisse JC, Maquart FX, Borel JP. Does oxygen free radical increased formation explain long-term complications of diabetes mellitus? Med Hypotheses 29:47-50, 1989.
12. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 55:1139-1149, 1998.
13. Foulis AK, McGill M, Farquharson MA, Hilton DA. A search for evidence of viral infection in pancreases of newly diagnosed patients with IDDM. Diabetologia 40:53-61, 1997.
14. Taylor KW. Conference report: CIBA Foundation meeting on entero-viruses and early childhood diabetes. Diabet Med 13:910-911, 1996.
15. Helgason T, Jonasson MR. Evidence for a food additive as a cause of ketosis-prone diabetes. Lancet 2:716-720, 1981.
16. Dahlquist GG, Blom LG, Persson LA, Sandstrom AI, Wall SG. Dietary factors and the risk of developing insulin-dependent diabetes in childhood. BMJ 300:1302-1306, 1990.
17. Scott FW, Marliss EB. Conference summary: Diet as an environmental factor in development of insulin-dependent diabetes mellitus. Can J Physiol Pharmacol 69:311-319, 1991.
18. Maxwell SR, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GH, Jones AF, Barnett AH. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:484-490, 1997.
19. Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 21:1736-1742, 1998.
20. Santini SA, Marra G, Giardina B, Cotroneo P, Mordente A, Martorana GE, Manto A, Ghirlanda G. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46:1853-1858, 1997.
21. Rocic B, Vucic M, Knezevic-Cuca J, Radica A, Pavlic-Renar I, Profozic V, Metelko Z. Total plasma antioxidants in first-degree relatives of patients with insulin-dependent diabetes. Exp Clin Endocrinol Diabetes 105:213-217, 1997.
22. Zonana J, Rimoin DL. Inheritance of diabetes mellitus. N Engl J Med 295:603-605, 1976.
23. Adams DD, Adams YJ, Knight JG, McCall J, White P, Horrocks R, van Loghem E. A solution to the genetic and environmental puzzles of insulin-dependent diabetes mellitus. Lancet 1:420-424, 1984.
24. Suciu-Foca N, Nicholson JF, Reemtsma K, Rubinstein P. The HLA system and the genetics of juvenile diabetes mellitus. Diabetes Metab 3:193-198, 1977.
25. Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins: A study of 200 pairs. Diabetologia 20:87-93, 1981.
26. Lazarow A. Protective effect of glutathione and cysteine against alloxan diabetes in the rat. Proc Soc Exp Biol Med 61:441-447, 1946.
27. Heikkila RE, Winston B, Cohen G. Alloxan-induced diabetes: Evidence for hydroxyl radical as a cytotoxic intermediate. Biochem Pharmacol 25:1085-1092, 1976.
28. Malaisse WJ. Alloxan toxicity to the pancreatic β-cell: A new hypothesis. Biochem Pharmacol 31:3527-3534, 1982.
29. Cohen G, Heikkila RE. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249:2447-2452, 1974.
30. Fehsel K, Kroncke KD, Kolb-Bachofen V. The action of NO and its role in autoimmune diabetes mellitus. Res Immunol 146:711-715, 1995.
31. Kroncke KD, Fehsel K, Sommer A, Rodriguez ML, Kolb-Bachofen V. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol Chem Hoppe Seyler 376:179-185, 1995.
32. Kolb H, Kiesel U, Kroncke KD, Kolb-Bachofen V. Suppression of low-dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sci 49:L213-L217, 1991.
33. Flodstrom M, Tyrberg B, Eizirik DL, Sandler S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 48:706-713, 1999.
34. Nathan CF, Tsunawaki S. Secretion of toxic oxygen products by macrophages: Regulatory cytokines and their effects on the oxidase. Ciba Found Symp 118:211-230, 1986.
35. Rabinovitch A, Suarez-Pinzon WL, Strynadka K, Lakey JR, Rajotte RV. Human pancreatic islet β-cell destruction by cytokines involves oxygen free radicals and aldehyde production. J Clin Endocrinol Metab 81:3197-3202, 1996.
36. Fischer LJ, Hamburger SA. Inhibition of alloxan action in isolated pancreatic islets by superoxide dismutase, catalase, and a metal chelator. Diabetes 29:213-216, 1980.
37. Fischer LJ, Hamburger SA. Dimethylurea: A radical scavenger that protects isolated pancreatic islets from the effects of alloxan and dihydroxyfumarate exposure. Life Sci 26:1405-1409, 1980.
38. Gandy SE, Buse MG, Crouch RK. Protective role of superoxide dismutase against diabetogenic drugs. J Clin Invest 70:650-658, 1982.
39. Sandler S, Welsh M, Andersson A. Streptozotocin-induced impairment of islet β-cell metabolism and its prevention by a hydroxyl radical scavenger and inhibitors of poly(ADP-ribose) synthetase. Acta Pharmacol Toxicol (Copenh) 53:392-400, 1983.
40. Sandler S, Andersson A. The partial protective effect of the hydroxyl radical scavenger dimethyl urea on streptozotocin-induced diabetes in the mouse in vivo and in vitro. Diabetologia 23:374-378, 1982.
41. Mendola J, Wright JR Jr., Lacy PE. Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozocin-induced insulitis. Diabetes 38:379-385, 1989.
42. Robbins MJ, Sharp RA, Slonim AE, Burr IM. Protection against streptozotocin-induced diabetes by superoxide dismutase. Diabetologia 18:55-58, 1980.
43. Sumoski W, Baquerizo H, Rabinovitch A. Oxygen free-radical scavengers protect rat islet cells from damage by cytokines. Diabetologia 32:792-796, 1989.
44. Kubisch HM, Wang J, Bray TM, Phillips JP. Targeted overexpression of Cu/Zn superoxide dismutase protects pancreatic β-cells against oxidative stress. Diabetes 46:1563-1566, 1997.
45. Kubisch HM, Wang J, Luche R, Carlson E, Bray TM, Epstein CJ, Phillips JP. Transgenic copper/zinc superoxide dismutase modulates susceptibility to type I diabetes. Proc Natl Acad Sci U S A 91:9956-9959, 1994.
46. Ho E, Chen G, Bray TM. Supplementation of N-acetylcysteine inhibits NFkB activation and protects against alloxan-induced diabetes in CD-1 mice. FASEB J 13:1845-1854, 1999.
47. Tabatabaie T, Kotake Y, Wallis G, Jacob JM, Floyd RA. Spin trapping agent phenyl N-tert-butylnitrone protects against the onset of drug-induced insulin-dependent diabetes mellitus. FEBS Lett 407:148-152, 1997.
48. Kim JY, Chi JK, Kim EJ, Park SY, Kim YW, Lee SK. Inhibition of diabetes in non-obese diabetic mice by nicotinamide treatment for 5 weeks at the early age. J Korean Med Sci 12:293-297, 1997.
49. 2 radicals in autoimmune diabetes. Immunol Cell Biol 67:85-87, 1989.
50. Nomikos IN, Prowse SJ, Carotenuto P, Lafferty KJ. Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 35:1302-1304, 1986.
51. Behrens WA, Scott FW, Madere R, Trick K, Hanna K. Effect of dietary vitamin E on the vitamin E status in the BB rat during development and after the onset of diabetes. Ann Nutr Metab 30:157-165, 1986.
52. Hayward AR, Shriber M, Sokol R. Vitamin E supplementation reduces the incidence of diabetes but not insulitis in NOD mice [see comments]. J Lab Clin Med 119:503-507, 1992.
53. Rabinovitch A, Suarez WL, Power RF. Lazaroid antioxidant reduces incidence of diabetes and insulitis in nonobese diabetic mice. J Lab Clin Med 121:603-607, 1993.
54. Roza AM, Slakey DP, Pieper GM, Van Ye TM, Moore-Hilton G, Komorowski RA, Johnson CP, Hedlund BE, Adams MB. Hydroxy-ethyl starch deferoxamine, a novel iron chelator, delays diabetes in BB rats. J Lab Clin Med 123:556-560, 1994.
55. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 20:463-466, 1996.
56. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46:1733-1742, 1997.
57. Gorus FK, Malaisse WJ, Pipeleers DG. Selective uptake of alloxan by pancreatic β-cells. Biochem J 208:513-515, 1982.
58. Malaisse WJ, Malaisse-Lagae F, Sener A, Pipeleers DG. Determinants of the selective toxicity of alloxan to the pancreatic β cell. Proc Natl Acad Sci U S A 79:927-930, 1982.
59. Ferner RE. Drug-induced diabetes. Baillieres Clin Endocrinol Metab 6:849-866, 1992.
60. Palmer HJ, Paulson KE. Reactive oxygen species and antioxidants in signal transduction and gene expression. Nutr Rev 55:353-361, 1997.
61. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription [see comments]. FASEB J 10:709-720, 1996.
62. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-κB by a post-translational mechanism. Cell 47:921-928, 1986.
63. Baeuerle PA, Henkel T. Function and activation of NFκB in the immune system. Annu Rev Immunol 12:141-179, 1994.
64. Baeuerle PA, Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NFκB transcription factor. Cell 53:211-217, 1988.
65. Baeuerle PA, Baltimore D. IκB: A specific inhibitor of the NFκB transcription factor. Science 242:540-546, 1988.
66. Baldwin AS Jr. The NFκB and IκB proteins: New discoveries and insights. Annu Rev Immunol 14:649-683, 1996.
67. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485-1488, 1995.
68. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NFκB activation in response to diverse stimuli. EMBO J 14:2876-2883, 1995.
69. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NFκB activation. Cell 91:243-252, 1997.
70. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NFκB [see comments]. Nature 388:548-554, 1997.
71. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IκB kinase-β: NFκB activation and complex formation with IκB kinase-α and NIK [see comments]. Science 278:866-869, 1997.
72. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IκB kinase. Cell 90:373-383, 1997.
73. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 15:351-369, 1997.
74. Winyard PG, Blake DR. Antioxidants, redox-regulated transcription factors, and inflammation. Adv Pharmacol 38:403-421, 1997.
75. Siebenlist U, Franzoso G, Brown K. Structure, regulation, and function of NFκB. Annu Rev Cell Biol 10:405-455, 1994.
76. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NFκB and cytokine-inducible enhancers. FASEB J 9:899-909, 1995.
77. Kwon G, Corbett JA, Rodi CP, Sullivan P, McDaniel ML. Interleukin-1 β-induced nitric oxide synthase expression by rat pancreatic β-cells: Evidence for the involvement of nuclear factor kappa B in the signaling mechanism. Endocrinology 136:4790-4795, 1995.
78. Kwon G, Corbett JA, Hauser S, Hill JR, Turk J, McDaniel ML. Evidence for involvement of the proteasome complex (26S) and NFκB in IL-1β-induced nitric oxide and prostaglandin production by rat islets and RINm5F cells. Diabetes 47:583-591, 1998.
79. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: An oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res 17:221-237, 1992.
80. Muller JM, Rupee RA, Baeuerle PA. Study of gene regulation by NFκB and AP-1 in response to reactive oxygen intermediates. Methods 11:301-312, 1997.
81. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NFκB transcription factor and HIV-1. EMBO J 10:2247-2258, 1991.
82. Aillet F, Gougerot-Pocidalo MA, Virelizier JL, Israel N. Appraisal of potential therapeutic index of antioxidants on the basis of their in vitro effects on HIV replication in monocytes and interleukin 2-induced lymphocyte proliferation. AIDS Res Hum Retroviruses 10:405-411, 1994.
83. Suzuki YJ, Packer L. Inhibition of NFκB activation by vitamin E derivatives. Biochem Biophys Res Commun 193:277-283, 1993.
84. Offermann MK, Lin JC, Mar EC, Shaw R, Yang J, Medford RM. Antioxidant-sensitive regulation of inflammatory-response genes in Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 13:1-11, 1996.
85. Makropoulos V, Bruning T, Schulze-Osthoff K. Selenium-mediated inhibition of transcription factor NFκB and HIV-1 LTR promoter activity. Arch Toxicol 70:277-283, 1996.
86. Harakeh S, Jariwalla RJ. NFκB-independent suppression of HIV expression by ascorbic acid. AIDS Res Hum Retroviruses 13:235-239, 1997.
87. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol 157:1630-1637, 1996.
88. Cominacini L, Garbin U, Lo Cascio V. The need for a "free radical initiative" [comment]. Diabetologia 39:364-366, 1996.
89. Asayama K, Nyfeler F, English D, Pilkis SJ, Burr IM. Alloxan-induced free radical production in isolated cells: Selective effect on islet cells. Diabetes 33:1008-1011, 1984.
90. Rabinovitch A, Suarez WL, Thomas PD, Strynadka K, Simpson I. Cytotoxic effects of cytokines on rat islets: Evidence for involvement of free radicals and lipid peroxidation. Diabetologia 35:409-413, 1992.
91. McDaniel ML, Kwon G, Hill JR, Marshall CA, Corbett JA. Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 211:24-32, 1996.
92. Heller B, Burkart V, Lampeter E, Kolb H. Antioxidant therapy for the prevention of type I diabetes. Adv Pharmacol 38:629-638, 1997.
93. Wu G. Nitric oxide synthesis and the effect of aminoguanidine and NG-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 44:360-364, 1995.
94. Holstad M, Jansson L, Sandler S. Inhibition of nitric oxide formation by aminoguanidine: An attempt to prevent insulin-dependent diabetes mellitus. Gen Pharmacol 29:697-700, 1997.
95. Hammes HP, Ali SS, Uhlmann M, Weiss A, Federlin K, Geisen K, Brownlee M. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia 38:269-273, 1995.
96. Kolb H, Burkart V. Nicotinamide in type 1 diabetes: Mechanism of action revisited. Diabetes Care 22(Suppl 2):B16-B20, 1999.
97. Pozzilli P, Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Romiti A, Giovannini C, Lucentini L, Matteoli MC, Crino A, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci C, Multari G, Suppa M, Sulli N, De Mattia G, Faldetta MR, Suraci MT. Vitamin E and nicotinamide have similar effects in maintaining residual β-cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study) [published erratum appears in Eur J Endocrinol 137:558, 1997] Eur J Endocrinol 137:234-239, 1997.
98. Pozzilli P, Visalli N, Signore A, Baroni MG, Buzzetti R, Cavallo MG, Boccuni ML, Fava D, Gragnoli C, Andreani D et al. Double-blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 38:848-852, 1995.
99. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H. The Deutsche Nicotinamide Intervention Study: An attempt to prevent type 1 diabetes. DENIS Group. Diabetes 47:980-984, 1998.
100. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: A pivotal role in the systemic inflammatory response syndrome and new target for therapy [see comments]. Intensive Care Med 24:1131-1138, 1998.
101. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45:7-17, 1999.
102. Sprong RC, Winkelhuyzen-Janssen AM, Aarsman CJ, van Oirschot JF, van der Bruggen T, van Asbeck BS. Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am J Respir Crit Care Med 157:1283-1293, 1998.
103. Lee JI, Burckart GJ. Nuclear factor kappa B: Important transcription factor and therapeutic target. J Clin Pharmacol 38:981-993, 1998.